Pneumonia, Viral Clinical Trial
Official title:
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients: Multicenter Interventional Study
Due to the limitations of COVID-19 treatment and in the absence of licensed antiviral for
COVID-19, the historical choice of therapeutic convalescent plasma (CP) is considered
especially against RNA viruses .It was known that convalescent plasma does not only
neutralize the pathogens but provide passive immunomodulatory properties that allows the
recipient to control the exaggerated inflammatory cascade. However, still there is a lack of
understanding of the mechanism of action of CCP therapeutic components. Reports from open
label trials and case series show that CCP is safe and might be effective in severe cases
with COVID-19 . Therefore, the World health organisation (WHO) and Food and Drug
Administration (FDA) issued guidelines for the CCP usage and standardised the donor selection
, which was further supported by Emergency use Authorisation (EUA) .
Therefore, the aim in the current study is to assess the effect of CCP on time to clinical
improvement, hospital mortality and to evaluate the changes on oxygen saturation and
laboratory markers (lymphocyte counts and C-reactive protein) compared with standard
treatment alone in patients with moderate or severe COVID-19 disease.
This is a prospective multicenter interventional observational study will be conducted in 4 major tertiary hospitals (Al-Sabah, Farwaniya , Mubarak Al-Kabeer and Jahra) in Kuwait . ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04517123 -
Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The "PRONE" Study
|
N/A | |
| Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
| Completed |
NCT01271842 -
Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study
|
N/A | |
| Completed |
NCT04724538 -
Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04414293 -
Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis
|
N/A | |
| Completed |
NCT04047719 -
Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
|
||
| Recruiting |
NCT04528888 -
Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection
|
Phase 3 | |
| Completed |
NCT04606407 -
Inhaled NO for the Treatment of Viral Pneumonia in Adults
|
N/A | |
| Terminated |
NCT04619693 -
Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia
|
||
| Recruiting |
NCT05077917 -
Cromolyn Sodium for Treatment of COVID-19 Pneumonia
|
Phase 3 | |
| Withdrawn |
NCT04381923 -
COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia
|
N/A | |
| Recruiting |
NCT05976581 -
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
|
N/A | |
| Active, not recruiting |
NCT04381364 -
Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)
|
Phase 2 | |
| Completed |
NCT04422613 -
Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia
|
N/A | |
| Completed |
NCT04479540 -
Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease
|
N/A | |
| Completed |
NCT04424836 -
HFNC Treatment in COVID-19 Pneumonia
|
||
| Active, not recruiting |
NCT04365101 -
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04387799 -
Determinants of COVID-19 Pneumonia (MC-19)
|
||
| Completed |
NCT04382547 -
Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04399681 -
The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19
|
N/A |